Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOAR trial of eltrombopag + cyclosporine for first-line severe acquired aplastic anemia
NL-OMON50032Phase 2Withdrawn
- Sponsor
- Novartis
- Start
- Mar 2017
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eltrombopag and cyclosporine in acquired aplastic anemia (AAA), sponsored by Novartis. Primary endpoint: Overall hematologic response by 6 months. Planned start Mar 2017; status: withdrawn.
02
Drugs
eltrombopagcyclosporine
03
Conditions
acquired aplastic anemia (AAA)
Beyond the preview
Go deeper on NL-OMON50032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50032.